Email this article Luteinizing hormone-releasing hormone antagonists in patients with prostate cancer. A standard approach and the results of innovative studies
- Authors: Nyushko K.M.1,2, Alekseev B.Y.1,3,4, Kalpinsky A.S.1,3,5,6, Kaprin A.D.1,3,4
-
Affiliations:
- P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia
- 3, Second Botkinsky Pr., Moscow 125284
- 3, Second Botkinsky Pr., Moscow 125284 Department of Urology with Course of Urologic Oncology, Faculty for Postgraduate Training of Health Workers, Peoples’ Friendship University of Russia
- 21, Miklukho-Maklai St., Moscow 117198
- 21, Miklukho-Maklai St., Moscow 117198 Department of Oncology, Medical Institute for Postgraduate Training of Physicians, Moscow State University of Food Productions
- 11, Volokolamskoye Shosse, Moscow 125080, Russia
- Issue: Vol 10, No 4 (2014)
- Pages: 70-74
- Section: PROSTATE CANCER
- Published: 30.12.2014
- URL: https://oncourology.abvpress.ru/oncur/article/view/399
- DOI: https://doi.org/10.17650/1726-9776-2014-10-4-70-74
- ID: 399
Cite item
Full Text
Abstract
Prostate cancer (PC) is one of the most burning problems of modern urologic oncology. Hormonal therapy (HT) using medical castration
remains a basic therapy for metastatic PC. HT with a novel class of luteinizing hormone-releasing hormone (LHRH) receptor antagonists is
a promising and effective castration treatment option that has a number of significant advantages over LHRH analogues. The paper reviews the results of trials comparing the efficiency and adverse reactions of HT using LHRH antagonists and analogues and gives those of a Russian multicenter study covering the countrywide experience with degarelix.
About the authors
K. M. Nyushko
P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia; 3, Second Botkinsky Pr., Moscow 125284
Author for correspondence.
Email: kirandja@yandex.ru
Russian Federation
B. Ya. Alekseev
P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia; 3, Second Botkinsky Pr., Moscow 125284Department of Urology with Course of Urologic Oncology, Faculty for Postgraduate Training of Health Workers, Peoples’ Friendship University of Russia; 21, Miklukho-Maklai St., Moscow 117198
Russian Federation
A. S. Kalpinsky
P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia; 3, Second Botkinsky Pr., Moscow 125284Department of Urology with Course of Urologic Oncology, Faculty for Postgraduate Training of Health Workers, Peoples’ Friendship University of Russia; 21, Miklukho-Maklai St., Moscow 117198
Department of Oncology, Medical Institute for Postgraduate Training of Physicians, Moscow State University of Food Productions; 11, Volokolamskoye Shosse, Moscow 125080, Russia
Russian Federation
A. D. Kaprin
P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia; 3, Second Botkinsky Pr., Moscow 125284Department of Urology with Course of Urologic Oncology, Faculty for Postgraduate Training of Health Workers, Peoples’ Friendship University of Russia; 21, Miklukho-Maklai St., Moscow 117198
Russian Federation
References
Supplementary files
